Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone303-625-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$55.51 million
Profitability
Miscellaneous
Employees360
Next Earnings Date2/26/2019 (Confirmed)
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the Zacks' consensus estimate of ($1.60) by $0.11. The biopharmaceutical company had revenue of $22.76 million for the quarter, compared to the consensus estimate of $30.11 million. Clovis Oncology had a negative net margin of 390.65% and a negative return on equity of 108.92%. The business's quarterly revenue was up 35.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.24) EPS. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
How can I listen to Clovis Oncology's earnings call?
Clovis Oncology will be holding an earnings conference call on Tuesday, February 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for CLVS?
14 brokerages have issued 12 month target prices for Clovis Oncology's shares. Their forecasts range from $16.00 to $110.00. On average, they expect Clovis Oncology's share price to reach $55.5018 in the next twelve months. This suggests a possible upside of 119.2% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
Has Clovis Oncology been receiving favorable news coverage?
News stories about CLVS stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clovis Oncology earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the next few days.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Alkermes (ALKS), Patheon (PTHN), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC) and Ultragenyx Pharmaceutical (RARE).
What other stocks do shareholders of Clovis Oncology own?
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (5.22%), Samlyn Capital LLC (1.91%), Geode Capital Management LLC (1.09%), Elk Creek Partners LLC (0.72%), KBC Group NV (0.60%) and Dimensional Fund Advisors LP (0.60%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which institutional investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Amundi Pioneer Asset Management Inc., Hudson Bay Capital Management LP, Bank of Montreal Can, MetLife Investment Advisors LLC, Principal Financial Group Inc., Stifel Financial Corp and California Public Employees Retirement System. Company insiders that have sold Clovis Oncology company stock in the last year include Lindsey Rolfe and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which institutional investors are buying Clovis Oncology stock?
CLVS stock was purchased by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Orbimed Advisors LLC, Elk Creek Partners LLC, Dimensional Fund Advisors LP, Sofinnova Investments Inc., Candriam Luxembourg S.C.A., KBC Group NV and Squarepoint Ops LLC. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $25.32.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $1.33 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
